|
pubmed:abstractText |
In type 2 diabetic patients with no cardiac history or symptoms, 1) to evaluate whether the soluble forms of Fas (sFas) and Fas-ligand (sFasL), involved in apoptosis, may be markers of silent coronary disease or related to hypertension or microangiopathic complications; 2) to examine the effect of short-term glycemic control on sFas and sFasL.
|
|
pubmed:affiliation |
Department of Diabetology-Endocrinology-Nutrition, AP-HP, Paris-Nord University, Jean Verdier Hospital, and Laboratory of Nutrition and Metabolic Diseases, Paris-Nord University, Bondy, France.
|
